サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1544038

筋萎縮性側索硬化症の世界市場

Amyotrophic Lateral Sclerosis

出版日
ページ情報
英文 183 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
筋萎縮性側索硬化症の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

筋萎縮性側索硬化症の世界市場は2030年までに36億米ドルに達する

2023年に10億米ドルと推定される筋萎縮性側索硬化症の世界市場は、2030年には36億米ドルに達し、分析期間2023-2030年のCAGRは19.4%で成長すると予測されます。

米国市場は2億8,580万米ドルと推定、中国はCAGR18.4％で成長予測

米国の筋萎縮性側索硬化症市場は、2023年に2億8,580万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億3,450万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは18.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ17.1%と16.4%と予測されています。欧州では、ドイツがCAGR約14.2%で成長すると予測されています。

世界の筋萎縮性側索硬化症市場- 主要動向と促進要因まとめ

筋萎縮性側索硬化症（ALS）とは何か、身体にどのような影響を与えるのか？

ルー・ゲーリッグ病としても知られる筋萎縮性側索硬化症（ALS）は、脳や脊髄の神経細胞を侵す進行性の神経変性疾患です。この疾患は、随意筋の制御に不可欠な運動ニューロンが徐々に変性し、死滅します。これらのニューロンが劣化すると、患者は筋力低下、痙攣を経験し、最終的には筋肉の動きを開始し制御する能力を失う。その結果、会話、嚥下、呼吸が困難になるなど、重度の身体障害を引き起こします。ALSの進行速度は個人差があるもの、ALSは必ず麻痺を引き起こし、最終的には致死的となり、大半の患者は発症から3～5年以内に呼吸不全に陥る。ALSの性質を理解することは、効果的な治療法を開発し、罹患者に包括的なケアを提供するために極めて重要です。

ALSの調査と治療はどのように進歩しているのか？

ALSの研究は急速に進展しており、その基礎となるメカニズムの解明や潜在的な治療法の開発に焦点を当てた研究が数多く行われています。遺伝学的研究により、家族性ALSに関連するいくつかの遺伝子変異が同定され、遺伝性のALSに対する洞察が得られ、標的治療の道が開かれました。バイオマーカーの開発も重要な分野であり、診断の改善、疾患の進行のモニタリング、治療効果の評価を目指しています。現在、ALSの治療薬として承認されているのは、リルゾールやエダラボンなど数種類のみで、病気の進行を遅らせる効果はわずかです。しかし、現在進行中の臨床試験では、遺伝子治療、幹細胞治療、神経保護剤の使用など、様々なアプローチが模索されています。また、技術の進歩により、ALS患者の脳信号によるコミュニケーションや機器操作を支援するブレイン・コンピューター・インターフェイスのような革新的な治療法も開発されています。ALS患者の生活の質（QOL）と予後を改善するためには、このような研究と治療戦略の発展が不可欠です。

ALSの治療にはどのような課題と機会があるのか？

ALSは急速に進行し、深刻な影響を及ぼす病気であるため、その治療には大きな課題があります。神経科医、理学療法士、言語療法士、その他のヘルスケア専門家が参加する集学的治療は、ALS患者の複雑なニーズに対応するために不可欠です。専門的なケアセンターや支援サービスを利用することは、病気の管理を強化することにつながるが、地理的・経済的な障壁があるため、このようなアクセスが制限されることが多いです。さらに、患者や介護者の精神的・心理的負担は大きく、包括的なサポートシステムが必要です。このような課題にもかかわらず、遠隔医療や支援機器などの技術革新により、遠隔支援を提供し、患者の自立性を高めることで、ケアを改善する機会があります。また、研究資金を確保し、ALSに対する一般の理解を深め、最終的に患者の転帰と支援ネットワークの改善に貢献するためには、擁護と啓蒙活動も重要です。

ALS治療市場成長の原動力は？

筋萎縮性側索硬化症（ALS）市場の成長は、医学研究の進歩、病気に対する認知度の向上、革新的な治療法の開発など、いくつかの要因によって牽引されています。遺伝子マーカーの同定や高度な画像診断技術の使用といった技術の進歩は、ALSの理解と診断を強化しています。政府・非政府組織によるALS研究への資金援助が増加し、新しい治療法の開発や臨床試験に拍車がかかっています。また、ALSの発症率は年齢とともに増加するため、効果的な治療法に対する需要の高まりも高齢化社会を後押ししています。加えて、患者支援団体や啓発キャンペーンの拡大が早期診断や治療へのアクセス向上につながり、市場の成長をさらに促進しています。製薬会社は、遺伝子治療や神経保護剤など、病気の経過を変えることが期待できる新規治療法の開発にますます投資するようになっています。これらの要因が相まって、ALS治療市場の勢いは持続しており、将来的には治療法の改善や治癒の可能性が期待されています。

調査対象企業の例（注目23社）

  • AB Science SA
  • Apotex, Inc.
  • Aquestive
  • Biogen, Inc.
  • Brainstorm Cell Therapeutics Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Genervon Biopharmaceuticals LLC
  • Ionis Pharmaceuticals, Inc.
  • Kringle Pharma Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralstem, Inc.
  • Orion Corporation
  • Orphazyme A/S
  • Sanofi SA
  • Treeway BV
  • Valeant Pharmaceuticals International, Inc.
  • ViroMed Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP10278

Global Amyotrophic Lateral Sclerosis Market to Reach US$3.6 Billion by 2030

The global market for Amyotrophic Lateral Sclerosis estimated at US$1.0 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 19.4% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$285.8 Million While China is Forecast to Grow at 18.4% CAGR

The Amyotrophic Lateral Sclerosis market in the U.S. is estimated at US$285.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$534.5 Million by the year 2030 trailing a CAGR of 18.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.1% and 16.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.2% CAGR.

Global Amyotrophic Lateral Sclerosis Market - Key Trends and Drivers Summarized

What is Amyotrophic Lateral Sclerosis (ALS) and How Does It Impact the Body?

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. This condition leads to the gradual degeneration and death of motor neurons, which are essential for controlling voluntary muscles. As these neurons deteriorate, patients experience muscle weakness, twitching, and eventually, the loss of the ability to initiate and control muscle movement. This leads to severe physical impairments, including difficulties in speaking, swallowing, and breathing. Despite the varying progression rates among individuals, ALS invariably leads to paralysis and is ultimately fatal, with the majority of patients succumbing to respiratory failure within three to five years from the onset of symptoms. Understanding the nature of ALS is crucial for developing effective treatments and providing comprehensive care for those affected.

How Are Research and Treatments Evolving for ALS?

Research into ALS is rapidly advancing, with numerous studies focusing on understanding its underlying mechanisms and developing potential treatments. Genetic research has identified several gene mutations associated with familial ALS, providing insights into its hereditary forms and opening avenues for targeted therapies. The development of biomarkers is another critical area, aiming to improve diagnosis, monitor disease progression, and evaluate treatment efficacy. Currently, only a few medications, such as Riluzole and Edaravone, are approved for ALS, offering modest benefits in slowing disease progression. However, ongoing clinical trials are exploring various approaches, including gene therapy, stem cell therapy, and the use of neuroprotective agents. Advances in technology are also facilitating innovative treatment modalities, such as brain-computer interfaces that help ALS patients communicate and control devices using their brain signals. These evolving research and treatment strategies are essential for improving the quality of life and prognosis for ALS patients.

What Challenges and Opportunities Exist in Managing ALS?

Managing ALS presents significant challenges, given the rapid progression and severe impact of the disease. Multidisciplinary care, involving neurologists, physical therapists, speech therapists, and other healthcare professionals, is vital for addressing the complex needs of ALS patients. Access to specialized care centers and support services can enhance disease management, but geographical and financial barriers often limit this access. Additionally, the emotional and psychological burden on patients and caregivers is substantial, necessitating comprehensive support systems. Despite these challenges, there are opportunities for improving care through technological innovations, such as telemedicine and assistive devices, which can provide remote support and enhance patient independence. Advocacy and awareness initiatives are also crucial for securing funding for research and improving public understanding of ALS, ultimately contributing to better patient outcomes and support networks.

What is Driving Market Growth for ALS Treatments?

The growth in the Amyotrophic Lateral Sclerosis (ALS) market is driven by several factors, including advancements in medical research, increasing awareness of the disease, and the development of innovative treatment approaches. Technological advancements, such as the identification of genetic markers and the use of advanced imaging techniques, are enhancing the understanding and diagnosis of ALS. The rise in funding for ALS research from both governmental and non-governmental organizations is spurring the development of new therapies and clinical trials. The growing demand for effective treatments is also driven by an aging population, as the incidence of ALS increases with age. Additionally, the expansion of patient advocacy groups and awareness campaigns is leading to earlier diagnosis and better access to care, further propelling market growth. Pharmaceutical companies are increasingly investing in the development of novel therapies, including gene therapies and neuroprotective agents, which hold promise for altering the course of the disease. These factors collectively are sustaining the momentum in the ALS treatment market, offering hope for improved management and potential cures in the future.

Select Competitors (Total 23 Featured) -

  • AB Science SA
  • Apotex, Inc.
  • Aquestive
  • Biogen, Inc.
  • Brainstorm Cell Therapeutics Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Genervon Biopharmaceuticals LLC
  • Ionis Pharmaceuticals, Inc.
  • Kringle Pharma Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralstem, Inc.
  • Orion Corporation
  • Orphazyme A/S
  • Sanofi SA
  • Treeway BV
  • Valeant Pharmaceuticals International, Inc.
  • ViroMed Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Amyotrophic Lateral Sclerosis - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of ALS Drives Adoption of Multidisciplinary Care Approaches
    • Increasing Genetic Research Throws the Spotlight On ALS Understanding
    • Advancements in Biomarkers Propel Growth in ALS Diagnosis and Treatment
    • Development of Gene Therapies Expands Addressable Market Opportunity
    • Innovations in Stem Cell Research Strengthen Business Case for ALS Treatments
    • Innovations in Brain-Computer Interfaces Enhance Patient Communication
    • Advances in Neuroprotective Agents Accelerate Demand for New ALS Therapies
    • Aging Population Expands Market Opportunity for ALS Treatments
    • Advances in Imaging Techniques Propel Growth in ALS Diagnostic Accuracy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Amyotrophic Lateral Sclerosis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • CHINA
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 24: Rest of Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Rest of Europe Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Asia-Pacific Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF WORLD
    • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of World Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR

IV. COMPETITION